Aligos Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
ALGS chart
What traders are saying about $ALGS
Latest postsAligos Therapeutics, Inc. news
- Aligos Therapeutics Stock Price Forecast. Should You Buy ALGS?
StockInvest.us ·
- Aligos Therapeutics, Inc. Estimates – NASDAQ:ALGS
TradingView ·
- US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Reuters ·
- Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Yahoo Finance ·
- Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Yahoo Finance ·
- Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
investorshub.advfn.com ·
- Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Yahoo Finance ·
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Yahoo Finance ·
- Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
Yahoo Finance ·
- Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Yahoo Finance ·
- ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
stocktwits.com ·
- Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Yahoo Finance ·
Aligos Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M |
| Diluted EPS | $-2.45 | $-20.94 | $-34.20 | $-2.25 |
| Total assets (year end) | $88.5M | $70.1M | $151.5M | $146.7M |
| Cash and equivalents (year end) | $18.3M | $37.0M | $135.7M | $81.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Aligos Therapeutics, Inc.
- Ticker
- ALGS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1799448
Frequently asked questions
What exchange is Aligos Therapeutics, Inc. listed on?
Aligos Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ALGS.
What industry is Aligos Therapeutics, Inc. in?
Aligos Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Aligos Therapeutics, Inc.'s fiscal year end?
Aligos Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Aligos Therapeutics, Inc. report?
Aligos Therapeutics, Inc. reported $2.2M in revenue for calendar year 2025, according to its SEC filings.